Benzbromarone, a uric acid transporter inhibitor used in the treatment of gout, inhibits the activity of GLUT9, MRP4, and BCRP [22, 23, 36, 37], which raises the question how endothelial uric acid concentrations are affected by this drug. The gene discussed is ABCC4; the disease is gout.